Investors in cash trouble should check out Heron Therapeutics Inc. (HRTX)

With 2.12 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.55 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.9977 whereas the lowest price it dropped to was $2.8800. The 52-week range on HRTX shows that it touched its highest point at $9.45 and its lowest point at $2.19 during that stretch. It currently has a 1-year price target of $10.42. Beta for the stock currently stands at 0.85.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRTX was down-trending over the past week, with a drop of -6.65%, but this was up by 18.47% over a month. Three-month performance dropped to -21.54% while six-month performance fell -2.64%. The stock lost -64.80% in the past year, while it has gained 18.00% so far this year. A look at the trailing 12-month EPS for HRTX yields -2.09 with Next year EPS estimates of -0.85. For the next quarter, that number is -0.28. This implies an EPS growth rate of 10.50% for this year and 47.90% for next year. EPS is expected to grow by 47.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 13.30%.

Float and Shares Shorts:

At present, 118.89 million HRTX shares are outstanding with a float of 118.39 million shares on hand for trading. On Oct 13, 2022, short shares totaled 29.18 million, which was 24.56% higher than short shares on Sep 14, 2022. In addition to Dr. Barry D. Quart Pharm.D. as the firm’s Chairman & CEO, Mr. John W. Poyhonen serves as its Pres & Chief Commercial Officer.

Institutional Ownership:

Through their ownership of 111.17% of HRTX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 66.75% of HRTX, in contrast to 6.36% held by mutual funds. Shares owned by individuals account for 38.10%. As the largest shareholder in HRTX with 9.92% of the stake, Franklin Advisers, Inc. holds 11,798,659 shares worth 11,798,659. A second-largest stockholder of HRTX, SSgA Funds Management, Inc., holds 8,838,706 shares, controlling over 7.43% of the firm’s shares. Deep Track Capital LP is the third largest shareholder in HRTX, holding 8,548,387 shares or 7.19% stake. With a 3.28% stake in HRTX, the JPMorgan Small Cap Growth Fund is the largest stakeholder. A total of 3,900,740 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.82% of HRTX stock, is the second-largest Mutual Fund holder. It holds 3,357,971 shares valued at 8.39 million. FTIF SICAV – Biotechnology Discov holds 2.67% of the stake in HRTX, owning 3,176,917 shares worth 7.94 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRTX since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HRTX analysts setting a high price target of $15.00 and a low target of $5.50, the average target price over the next 12 months is $10.08. Based on these targets, HRTX could surge 408.47% to reach the target high and rise by 86.44% to reach the target low. Reaching the average price target will result in a growth of 241.69% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. HRTX will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$1.67 being high and -$1.98 being low. For HRTX, this leads to a yearly average estimate of -$1.85. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Heron Therapeutics Inc. surprised analysts by -$0.00 when it reported -$0.38 EPS against a consensus estimate of -$0.38. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.44. The average estimate for the next quarter is thus -$0.32.

Summary of Insider Activity:

Insiders traded HRTX stock several times over the past three months with 5 Buys and 0 Sells. In these transactions, 192,900 shares were bought while 0 shares were sold. The number of buy transactions has increased to 38 while that of sell transactions has risen to 16 over the past year. The total number of shares bought during that period was 316,497 while 37,850 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *